WallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
16.41%
Industry
23.72%
Market
102.72%
NVO's earnings have grown slower (7.48% per year) than the US Biotechnology industry average (17.24%)
Performance
NVO's earnings have grown slower (7.48% per year) than the US market average (27.52%)
Performance
NVO's earnings growth is accelerating - its growth over the last year (16.41%) is above its 5-year compound annual rate (7.48%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
8.17%
Industry
787.63%
Market
36.32%
NVO's revenue has grown slower (3.87% per year) than the US Biotechnology industry average (141.8%)
Performance
NVO's revenue has grown slower (3.87% per year) than the US market average (17.66%)
Performance
NVO's revenue growth is accelerating - its growth over the last year (8.17%) is above its 5-year compound annual rate (3.87%)
Performance

NVO earnings and revenue history

Current Revenue
$20.1B
Current Earnings
$6.8B
Current Profit Margin
33.8%

NVO Return on equity

Current Company
71%
Current Industry
-34.7%
Current Market
30.7%
NVO's Return on Equity (71%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
30.5%
Current Industry
-9.4%
Current Market
6.4%
NVO is generating higher Return on Assets (30.5%) than the US Biotechnology industry average (-5.92%)
Performance

NVO Return on capital employed

Current Company
81.4%
Current Industry
3.9%

Novo Nordisk A S Earnings & Revenue FAQ

What were NVO's earnings last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q1 2021 earnings per share (EPS) of $0.87, up 16.35% year over year. Total Novo Nordisk A S earnings for the quarter were $2.00 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.75.

What was NVO's earnings growth in the past year?

As of Q3 2021, Novo Nordisk A S's earnings has grown 16.41% year over year. This is 7.31 percentage points lower than the US Biotechnology industry earnings growth rate of 23.72%. Novo Nordisk A S's earnings in the past year totalled $6.91 billion.

What was NVO's revenue last quarter?

Novo Nordisk A S (NYSE: NVO) reported Q1 2021 revenue of $5.37 billion up 7.71% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $4.98 billion.

What was NVO's revenue growth in the past year?

As of Q3 2021, Novo Nordisk A S's revenue has grown 8.17% year over year. This is 779.46 percentage points lower than the US Biotechnology industry revenue growth rate of 787.63%. Novo Nordisk A S's revenue in the past year totalled $20.46 billion.
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.